Synthetic carbohydrate-based vacinnes

Lines connect the coordinator with its partners. CORDIS does not always give exact coordinates for projects before 2014. These points are placed at city or country level.

Project objective

A fully synthetie candidate meningococcal vaccine will be developed which is composed of a synthetic carbohydrate B-epitope derived from meningococcal LPS, a synthetic peptide T-epitope and a lipopeptide. The synthetic methodology will be of general importance for synthetic carbohydrate-based vaccine development. The physical properties of the glycoconjugates will be studied by eleetron microscopy. The conjugates will be tested for T-cell recognition and experiments will be performed with peripheral blood mononucleated cells from HLA-typed volunteers. The conjugates will be used to evoke antibodies in mice and the T-cell-dependent properties of these antibodies will be examined. The antibodies will be determined by ELISA inhibition studies. The research will also provide a further understanding of the requirements for the induction of relevant T-helper reponce.

Original text from CORDIS.

Participants

• UNIVERSITY OF BIRMINGHAM · BIRMINGHAMCoordinatorUnited Kingdom
• Not availableCity levelItaly

Links

• View on CORDIS